Literature DB >> 23128598

Bufalin prevents the migration and invasion of T24 bladder carcinoma cells through the inactivation of matrix metalloproteinases and modulation of tight junctions.

Su Hyun Hong1, Gi-Young Kim, Young-Chae Chang, Sung-Kwon Moon, Wun-Jae Kim, Yung Hyun Choi.   

Abstract

Bufalin, a cardiotonic steroid extracted from toad venom, has generally been known to possess a range of biological activities; however, only a few studies have reported the anti-metastatic activity of bufalin. In the present study, we investigated the inhibitory effects of bufalin on cell migration and invasion, two critical cellular processes that are often deregulated during metastasis, using the human bladder cancer cell line, T24. Within the concentration range that was not cytotoxic, bufalin markedly inhibited the cell motility and invasiveness of T24 cells. The inhibitory effects of bufalin on cell invasiveness were associated with the tightening of tight junctions (TJs), which was demonstrated by an increase in transepithelial electrical resistance (TER). Bufalin treatment also repressed the levels of claudin proteins (claudin-2, -3 and -4) and the major components of TJs that play key roles in the control and selectivity of paracellular transport. Furthermore, the activities of matrix metalloproteinase (MMP)‑2 and -9 in T24 cells were dose‑dependently inhibited by treatment with bufalin and this also correlated with a decrease in their mRNA and protein expression levels; however, the mRNA and protein levels of the tissue inhibitor of metalloproteinase (TIMP)‑1 and -2 were increased. In addition, these effects were related to the increased phosphorylation of the extracellular signal-regulated protein kinase (ERK) pathway. The inhibition of ERK (PD98059) significantly prevented the bufalin‑induced suppression of T24 cell migration. These findings suggest that bufalin inhibits the migration and invasion of T24 cells by modulating the activity of TJs and MMPs, possibly in association with the activation of ERK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23128598     DOI: 10.3892/ijo.2012.1683

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

Review 1.  Molecular mechanisms underlying the antimetastatic activity of bufalin.

Authors:  Jie Wang; Yue Xia; Qingshong Zuo; Teng Chen
Journal:  Mol Clin Oncol       Date:  2018-03-21

2.  Bufalin, a bioactive component of the Chinese medicine chansu, inhibits inflammation and invasion of human rheumatoid arthritis fibroblast-like synoviocytes.

Authors:  Xiaofeng Rong; Weidong Ni; Yongguang Liu; Jun Wen; Chunyan Qian; Linke Sun; Jiajia Wang
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

3.  MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis.

Authors:  Yan-yan Qiu; Qiang Hu; Qing-feng Tang; Wen Feng; Song-jiao Hu; Bo Liang; Wen Peng; Pei-hao Yin
Journal:  Tumour Biol       Date:  2013-12-29

4.  Chansu inhibits the expression of cortactin in colon cancer cell lines in vitro and in vivo.

Authors:  Chun Li; Saeed M Hashimi; Siyu Cao; Ji Qi; David Good; Wei Duan; Ming Q Wei
Journal:  BMC Complement Altern Med       Date:  2015-07-02       Impact factor: 3.659

5.  Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-β receptors.

Authors:  Lei Zhao; Shizhou Liu; Xiaofang Che; Kezuo Hou; Yanju Ma; Ce Li; Ti Wen; Yibo Fan; Xuejun Hu; Yunpeng Liu; Xiujuan Qu
Journal:  Int J Mol Med       Date:  2015-06-30       Impact factor: 4.101

Review 6.  Transcriptional regulators of claudins in epithelial tight junctions.

Authors:  Niamat Khan; Abdul R Asif
Journal:  Mediators Inflamm       Date:  2015-04-08       Impact factor: 4.711

7.  Bufalin Induces Mitochondria-Dependent Apoptosis in Pancreatic and Oral Cancer Cells by Downregulating hTERT Expression via Activation of the JNK/p38 Pathway.

Authors:  Xin Tian; Shundong Dai; Jing Sun; Shenyi Jiang; Chengguang Sui; Fandong Meng; Yan Li; Liye Fu; Tao Jiang; Yang Wang; Jia Su; Youhong Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2015-12-10       Impact factor: 2.629

8.  Radiosynthesis and pharmacokinetics of [18F]fluoroethyl bufalin in hepatocellular carcinoma-bearing mice.

Authors:  Zhaoshuo Yang; Jianhua Liu; Qingqing Huang; Zhouji Zhang; Jiawei Zhang; Yanjia Pan; Yunke Yang; Dengfeng Cheng
Journal:  Onco Targets Ther       Date:  2017-01-11       Impact factor: 4.147

9.  Immunosuppressant MPA Modulates Tight Junction through Epigenetic Activation of MLCK/MLC-2 Pathway via p38MAPK.

Authors:  Niamat Khan; D V Krishna Pantakani; Lutz Binder; Muhammad Qasim; Abdul R Asif
Journal:  Front Physiol       Date:  2015-12-22       Impact factor: 4.566

10.  Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.

Authors:  Haiyong Wang; Chenyue Zhang; Litao Xu; Kun Zang; Zhouyu Ning; Feng Jiang; Huiying Chi; Xiaoyan Zhu; Zhiqiang Meng
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.